In another study, cancer cell-derived EVs were employed to efficaciously distribute CRISPR/Cas9 plasmids for the targeted suppression of poly (ADP-ribose) polymerase-1 (PARP-1), which promotes cell death (apoptosis) in ovarian cancer cells, improving their cisplatin sensitivity [290]. Here, PARP1 is linked to ovarian carcinoma.